<DOC>
	<DOCNO>NCT00151073</DOCNO>
	<brief_summary>Purpose : The aim clinical trail evaluate effectiveness Zoledronate ( Zometa ) combine Estramustine Docetaxel ( Taxotere ) treatment patient hormone-refractory prostate cancer .</brief_summary>
	<brief_title>Estramustine , Docetaxel Zoledronate Treatment Hormone-Refractory Adenocarcinoma Prostate</brief_title>
	<detailed_description>Hormone refractory prostate cancer refers advance disease patient long respond conventional hormonal treatment . When hormone therapy longer successful , chemotherapy treatment option . However , current single-agent treatment show limited benefit . In clinical trail , investigator evaluate effectiveness Zoledronate ( Zometa ) combine Estramustine Docetaxel ( Taxotere ) treatment patient hormone refractory prostate cancer . Zometa bisphosphonate , may reduce delay skeletal complication cause bone metastasis . Estramustine Taxotere chemotherapy drug show activity hormone refractory prostate cancer . Eligible patient randomize receive Estramustine Docetaxel ( Taxotere ) combination Zometa Zometa give alone .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>All patient must histologic diagnosis hormonerefractory adenocarcinoma prostate , hormone refractory disease must demonstrate appearance new lesion bone CT scan and/or rise PSA value . ( No evidence brain metastasis untreated spinal cord compression . ) Patients total androgen suppression therapy must undergo nonsteroidal antiandrogen withdrawal demonstrate rise PSA 4 week withdrawal flutamide 6 week withdrawal bicalutamide . Patient must undergo current chemotherapy , biologic therapy , investigational alternative anticancer direct therapy radiation therapy . Prior radiation therapy must complete 4 week prior registration . Patients may receive prior taxanebased cytotoxic chemotherapy hormone refractory disease .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Zometa</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Metastatic Prostate Cancer</keyword>
</DOC>